Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy
Julie L. Otte(Indiana University – Purdue University Indianapolis), Janet S. Carpenter(Indiana University – Purdue University Indianapolis), Suzanne Lemler, Laurie A. Wright(Johns Hopkins University), Anne Nguyen(Indiana University School of Medicine), Jill A. Hayden(Northwestern University), Anna Maria Storniolo(Indiana University Health), Vered Stearns(Johns Hopkins University), N. Lynn Henry(University of Michigan), Daniel F. Hayes(University of Michigan–Ann Arbor), David A. Flockhart(Indiana University – Purdue University Indianapolis), Bryan P. Schneider(Shanghai University of Traditional Chinese Medicine), Stacie C. Jeter(Johns Hopkins University), Faouzi Azzouz(Indiana University Health)
Menopause The Journal of The North American Menopause Society
June 30, 2009
Cited by 27
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k